| 24.25 -3.27 (-11.88%) | 04-23 12:42 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 33.9 | 1-year : | 35.82 |
| Resists | First : | 29.03 | Second : | 30.67 |
| Pivot price | 27.72  |
|||
| Supports | First : | 26.37 | Second : | 21.94 |
| MAs | MA(5) : | 27.26  |
MA(20) : | 27.94 |
| MA(100) : | 25.48 |
MA(250) : | 24.2 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 43.9 |
D(3) : | 30.8 |
| RSI | RSI(14): 51.5 |
|||
| 52-week | High : | 30.84 | Low : | 17.32 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BRP ] has closed below upper band by 37.5%. Bollinger Bands are 37.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 27.74 - 27.89 | 27.89 - 28.01 |
| Low: | 26.74 - 26.91 | 26.91 - 27.05 |
| Close: | 27.14 - 27.42 | 27.42 - 27.66 |
Mon, 10 Jul 2023
STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of NRx Pharmaceuticals, Inc. and Encourages ... - GlobeNewswire
Mon, 31 May 2021
Israeli Pharma Firm NeuroRx Completes SPAC Merger at $1.5B Valuation - NoCamels - Israeli Innovation News
Tue, 25 May 2021
NeuroRx set for $1.5b. SPAC IPO on Nasdaq - The Jerusalem Post
Tue, 25 May 2021
NeuroRx completes merger with SPAC, starts trading on Nasdaq - Drug Delivery Business News
Tue, 25 May 2021
NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and ... - PR Newswire
Thu, 20 May 2021
Don't Rush into SPAC IPOs + DPCM Capital (XPOA) taking Jam City Public - TheStreet
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 65 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 96.6 (%) |
| Shares Short | 3,970 (K) |
| Shares Short P.Month | 3,940 (K) |
| EPS | -1.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.73 |
| Profit Margin | -7.5 % |
| Operating Margin | 1.1 % |
| Return on Assets (ttm) | 0.8 % |
| Return on Equity (ttm) | -15.2 % |
| Qtrly Rev. Growth | 15.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 18.84 |
| EBITDA (p.s.) | 2.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 45 (M) |
| Levered Free Cash Flow | 268 (M) |
| PE Ratio | -18.72 |
| PEG Ratio | 0.5 |
| Price to Book value | 3.21 |
| Price to Sales | 1.48 |
| Price to Cash Flow | 40.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|